Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients
- 243 Downloads
Familial Mediterranean fever (FMF) patients suffer from chronic complications of disease such as AA amyloidosis, chronic arthritis, and spondylitis. Reduced quality of life (QoL) is a feature of chronic diseases but it is also impaired in patients with FMF. Despite the regular use of colchicine at a maximal dose, about 10% of patients do not respond well or resistant to colchicine (crFMF). IL-1 inhibitors have been shown to be effective in controlling attacks in crFMF patients. Herein, we aimed to investigate QoL changes of crFMF patients with IL-1 inhibitors.
All patients were prospectively monitored for the frequency, duration, severity of attacks, patient global assessments (Visual Analog Scale; VAS), and laboratory features. Either anakinra or canakinumab was used as IL-1 antagonist treatments. Demographic information, MEFV gene mutations, attack characteristics, and previous treatments were registered. Short form-36 (SF-36) quality of life scale was implemented by the interviewer for evaluating the QoL before and 3 months after the treatment.
A total of 44 patients were included in this study. Striking improvements were detected in frequency, duration, and VAS severity of attacks (p < 0.001). In the comparison of pre- and post-treatment, SF-36 sub-components significant improvements were observed on physical function, role limitation due to physical difficulty, role limitation due to emotional problem, energy, emotional well-being, social function, pain, general health, and health change.
In conclusion, IL-1 antagonists prevent attacks and improve QoL of crFMF.
KeywordsAnakinra Canakinumab Familial Mediterranean fever IL-1 antagonist Quality of life
Compliance with ethical standards
For use of IL-1 antagonists, off-label permission was obtained from regulatory authority and local ethics committee approved the study.
- 3.Tufan A, Ozturk MA (2017) Ailesel Akdeniz Ateşi: Güncel Tedavi Yaklaşımları. Turkiye Klinikleri J Rheumatol-Special Topics 10(1):37–45Google Scholar
- 4.Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690 CrossRefGoogle Scholar
- 5.Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 69(4):854–862. https://doi.org/10.1002/art.39995 CrossRefGoogle Scholar
- 6.De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Kone-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G (2018) Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378(20):1908–1919. https://doi.org/10.1056/NEJMoa1706314 CrossRefGoogle Scholar
- 7.Varan O, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A (2018) Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol:1–4. https://doi.org/10.1080/14397595.2018.1457469
- 8.Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, Katz SI, Kastner DL (2011) Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34(5):755–768. https://doi.org/10.1016/j.immuni.2011.02.020 CrossRefGoogle Scholar
- 11.Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S (2007) Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 34(7):1540–1544Google Scholar
- 13.Giese A, Kurucay M, Kilic L, Ornek A, Sendur SN, Lainka E, Henning BF (2013) Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects: a study evaluating the effect of disease severity and country of residence. Rheumatol Int 33(7):1713–1719. https://doi.org/10.1007/s00296-012-2622-y CrossRefGoogle Scholar
- 14.Press J, Neumann L, Abu-Shakra M, Bolotin A, Buskila D (2000) Living with a child with familial Mediterranean fever: does it affect the quality of life of the parents? Clin Exp Rheumatol 18(1):103–106Google Scholar
- 15.Sahin S, Yalcin I, Senel S, Ataseven H, Uslu A, Yildirim O, Semiz M (2013) Assesment life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci 17(7):958–963Google Scholar
- 16.Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885. https://doi.org/10.1002/1529-0131(199710)40:10<1879::AID-ART23>3.0.CO;2-M CrossRefGoogle Scholar
- 19.Kocyigit HAO, Fisek G, Olmez N, Memis A (1999) Validity and reliability of Turkish version of short form 36: a study of a patients with romatoid disorder. J Drug Ther (in Turkish) 12:102–106Google Scholar
- 20.Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, Langevitz P (1997) Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol 15(4):355–360Google Scholar
- 21.Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, Kasapcopur O, Kasifoglu T, Kisacik B, Ozdogan H, Tunca M, Acikel C, Vasculitis FMFA, Orphan disease research in pediatric r, Turkish FMFsg (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 73(5):897–901. https://doi.org/10.1136/annrheumdis-2013-204719 CrossRefGoogle Scholar
- 23.Hashkes PJ, Spalding SJ, Hajj-Ali R, Giannini EH, Johnson A, Barron KS, Weisman MH, Pashinian N, Reiff AO, Samuels J, Wright D, Lovell DJ, Huang B (2014) The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int 2014:854842. https://doi.org/10.1155/2014/854842 CrossRefGoogle Scholar